WO2021258654A1 - 一种银离子抑菌洗手液及其制备方法和应用 - Google Patents
一种银离子抑菌洗手液及其制备方法和应用 Download PDFInfo
- Publication number
- WO2021258654A1 WO2021258654A1 PCT/CN2020/134259 CN2020134259W WO2021258654A1 WO 2021258654 A1 WO2021258654 A1 WO 2021258654A1 CN 2020134259 W CN2020134259 W CN 2020134259W WO 2021258654 A1 WO2021258654 A1 WO 2021258654A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- parts
- silver
- silver ion
- ion antibacterial
- hand sanitizer
- Prior art date
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 75
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 51
- 239000004332 silver Substances 0.000 claims abstract description 35
- 229910052709 silver Inorganic materials 0.000 claims abstract description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000004359 castor oil Substances 0.000 claims abstract description 16
- 235000019438 castor oil Nutrition 0.000 claims abstract description 16
- 239000008367 deionised water Substances 0.000 claims abstract description 16
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 16
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 claims abstract description 16
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 16
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 claims abstract description 16
- 229910000367 silver sulfate Inorganic materials 0.000 claims abstract description 16
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 claims abstract description 16
- IGFHQQFPSIBGKE-UHFFFAOYSA-N Nonylphenol Natural products CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 claims abstract description 10
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical compound CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 claims abstract description 10
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000003906 humectant Substances 0.000 claims abstract description 9
- 239000003755 preservative agent Substances 0.000 claims abstract description 8
- 230000002335 preservative effect Effects 0.000 claims abstract description 6
- 235000001405 Artemisia annua Nutrition 0.000 claims description 16
- 240000000011 Artemisia annua Species 0.000 claims description 16
- 229940069445 licorice extract Drugs 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- 239000000284 extract Substances 0.000 claims description 14
- -1 skin conditioners Substances 0.000 claims description 12
- 239000001509 sodium citrate Substances 0.000 claims description 12
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 12
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical group OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 11
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical group CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 claims description 11
- 229960005323 phenoxyethanol Drugs 0.000 claims description 11
- 239000000796 flavoring agent Substances 0.000 claims description 8
- 235000019634 flavors Nutrition 0.000 claims description 8
- 239000011259 mixed solution Substances 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 7
- 239000000344 soap Substances 0.000 claims description 6
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 claims description 5
- 229940100524 ethylhexylglycerin Drugs 0.000 claims description 5
- 229960004063 propylene glycol Drugs 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- QMHBZWNZCSNBGU-UHFFFAOYSA-N nonane-1,2,3-triol Chemical compound CCCCCCC(O)C(O)CO QMHBZWNZCSNBGU-UHFFFAOYSA-N 0.000 claims description 2
- 230000002421 anti-septic effect Effects 0.000 claims 1
- 230000003385 bacteriostatic effect Effects 0.000 abstract description 2
- 231100000344 non-irritating Toxicity 0.000 abstract description 2
- 230000001139 anti-pruritic effect Effects 0.000 abstract 1
- 239000003908 antipruritic agent Substances 0.000 abstract 1
- 230000000249 desinfective effect Effects 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 34
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 25
- 238000012360 testing method Methods 0.000 description 12
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 244000052616 bacterial pathogen Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 4
- 229960004949 glycyrrhizic acid Drugs 0.000 description 4
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 4
- 235000019410 glycyrrhizin Nutrition 0.000 description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 4
- 206010011409 Cross infection Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 239000004378 Glycyrrhizin Substances 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 241001480043 Arthrodermataceae Species 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000032798 delamination Effects 0.000 description 2
- 230000037304 dermatophytes Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000000106 sweat gland Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000557876 Centaurea cineraria Species 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical class C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 206010040952 Skin warm Diseases 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229930101531 artemisinin Natural products 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- YPGCWEMNNLXISK-UHFFFAOYSA-N hydratropic acid Chemical class OC(=O)C(C)C1=CC=CC=C1 YPGCWEMNNLXISK-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000007853 structural degeneration Effects 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/524—Preservatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/596—Mixtures of surface active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
Definitions
- the invention belongs to the technical field of sanitary cleaning products, and specifically relates to a silver ion antibacterial hand sanitizer, and a preparation method and application thereof.
- silver is one of the tissue components in the human body.
- Cells treated with a very low concentration of silver ions have no obvious changes in cell aggregation, cell deformation, cell lysis, and pH. It can be seen that a small amount of silver ions can affect the human body. There is no obvious harmful effect. Therefore, the use of silver-based antibacterial agents for the improvement of the antibacterial function of textiles has sufficient safety.
- Chinese patent application CN 101766552 A discloses a no-washing antibacterial hand sanitizer and its preparation method, including 1g ⁇ 10g of chlorhexidine salt, 5ug ⁇ 1000ug of silver nitrate, 30 ⁇ 90ml of alcohol, 2g ⁇ 50g of skin care agent, and viscosity increasing Agent 0.5g ⁇ 3g, surfactant 0.5g ⁇ 3g, p+H regulator 0.5g ⁇ 5g, deionized water 15ml ⁇ 50ml.
- the product has a single disinfectant component, does not have synergistic antibacterial effect and strong spectral antibacterial and bactericidal effects, cannot be long-lasting antibacterial, and may cause a certain irritation to the skin.
- a silver ion antibacterial hand sanitizer comprising the following components and parts by weight:
- the silver ion antibacterial hand sanitizer is composed of the following components and parts by weight: 0.02 parts of silver, 0.05 parts of silver sulfate, 3 parts of humectant, 12 parts of skin conditioner, 0.5 part of preservative, and ten parts. 0.3 parts of sodium dialkylbenzene sulfonate, 1.2 parts of ethylhexyl glycerol, 3 parts of propylene glycol, 4 parts of nonylphenol polyether-14, 4 parts of PEG-50 castor oil, 0.02 parts of flavor, and 100 parts of deionized water.
- the humectant is methyl propylene glycol.
- the skin conditioning agent is composed of licorice extract, artemisia annua extract and sodium citrate in a weight ratio of 4-9:8-15:1-3.
- the skin conditioning agent is composed of licorice extract, artemisia annua extract and sodium citrate in a weight ratio of 6:13:2.
- the preservative is phenoxyethanol.
- the present invention also provides a preparation method of the silver ion antibacterial hand sanitizer, and the preparation steps are as follows:
- step S2 Cool down the mixed solution I obtained in step S1 to 20-30°C, then add silver, silver sulfate, skin conditioners, preservatives, and flavors, and homogenize at a pressure of 8-15MPa and a rotation speed of 2000-2500r/min Get it in 20-60 minutes.
- the added Artemisia annua extract contains flavonoids, coumarins, terpenes, phenylpropionic acids and volatile oils and other artemisinins, etc.; it has antimalarial, antibacterial, antiviral, anti-inflammatory, antipyretic and analgesic properties , Anti-schistosomiasis and other parasites, immunity, tumor suppression, affecting the cardiovascular system and other pharmacological effects; clinically often used for malaria, yin deficiency fever, bone steaming fever, summer evil fever, chronic bronchitis, disc lupus erythematosus, Oral mucosal lichen planus, skin fungal disease, neurodermatitis, skin pruritus, infant autumn diarrhea, epistaxis and other symptoms.
- the decoction of Artemisia annua L. has a strong inhibitory effect on Staphylococcus epidermidis, Catacoccus, Bacillus anthracis, and Bacillus diphtheria. It also has a certain inhibitory effect on Staphylococcus aureus, Pseudomonas aeruginosa, dysentery, tuberculosis and other bacilli. At a concentration of 0.25%, the volatile oil of Artemisia annua has an inhibitory effect on all dermatophytes, and at a concentration of 1%, it has a bactericidal effect on all dermatophytes.
- the added licorice extract is a medicinal ingredient extracted from licorice.
- Licorice extract generally contains: glycyrrhizin, glycyrrhizic acid, glycyrrhizin, glycyrrhizin, glycyrrhiza flavonoids, posterior thantanin, formononetin, quercetin, etc. It has the effects of invigorating the spleen and qi, clearing away heat and detoxification, eliminating phlegm and relieving cough, relieving emergency and relieving pain, and reconciling various medicines. It is used to treat symptoms such as weakness of the spleen and stomach, fatigue, palpitations, shortness of breath, coughing and excessive sputum, abdominal abdomen, and acute pain in limbs.
- adding a certain amount of sodium citrate to the skin conditioner can increase the stability of the Artemisia annua extract and licorice extract, effectively enhancing the antibacterial ability of the hand sanitizer, and at the same time make the hand sanitizer stable , Freezing and heating will not cause delamination, and the properties are reliable.
- the silver ion antibacterial hand sanitizer provided by the present invention has the following advantages:
- the silver ion antibacterial hand sanitizer provided by the present invention has the functions of sterilization, decontamination, antibacterial and disinfection, and also has high-efficiency moisturizing ingredients, moisturizes and keeps the skin warm, and is a mild and low-irritating hand sanitizer.
- the silver ion antibacterial hand sanitizer provided by the present invention has good stability, no delamination phenomenon occurs during freezing and heating, reliable properties, and achieves the sterilization effect of the chemical hand sanitizer. And the user is safe, non-toxic, non-irritating, and non-bad odor.
- the silver ion antibacterial hand sanitizer provided by the present invention combines a silver ion fungicide with plant extracts in a sterilization mode, which has good sterilization effect, has retention, and can kill viruses, and can kill skin, sweat glands and hair follicles continuously.
- the microorganisms escaping from it have a good aftereffect, sterilization and anti-inflammatory at the same time.
- Licorice extract was purchased from Nanjing Bangnuo Biological Technology Co., Ltd.
- Artemisia annua extract was purchased from Shanghai Lianmai Biological Engineering Co., Ltd.
- the remaining reagents used in the present invention are all commonly used reagents and can be purchased from conventional reagent production and sales companies.
- Example 1 A silver ion antibacterial hand sanitizer
- the skin conditioner is composed of licorice extract, artemisia annua extract and sodium citrate in a weight ratio of 4:15:3.
- the preparation steps are as follows:
- step S2 Cool down the mixed solution I obtained in step S1 to 20°C, then add silver, silver sulfate, skin conditioner, phenoxyethanol, and fragrance, and homogenize for 20 minutes at a pressure of 8MPa and a rotation speed of 2000r/min to obtain .
- Example 2 A silver ion antibacterial hand sanitizer
- the silver ion antibacterial hand sanitizer is composed of the following components and parts by weight:
- the skin conditioner is composed of licorice extract, artemisia annua extract and sodium citrate in a weight ratio of 6:13:2.
- the preparation steps are as follows:
- step S2 Cool down the mixed solution I obtained in step S1 to 25°C, then add silver, silver sulfate, skin conditioner, phenoxyethanol, and fragrance, and homogenize for 40 minutes at a pressure of 12MPa and a rotation speed of 2300r/min to obtain .
- the silver ion antibacterial hand sanitizer is composed of the following components and parts by weight:
- the preparation steps are as follows:
- step S2 Cool down the mixed solution I obtained in step S1 to 30°C, then add silver, silver sulfate, skin conditioner, phenoxyethanol, and fragrance, and homogenize for 60 minutes at a pressure of 15MPa and a rotation speed of 2500r/min, and it will be obtained .
- the silver ion antibacterial hand sanitizer is composed of the following components and parts by weight:
- the skin conditioner is composed of licorice extract and sodium citrate in a weight ratio of 6:2.
- the preparation method of the silver ion antibacterial hand sanitizer is similar to Example 2.
- Example 2 The difference from Example 2 is that the Artemisia annua extract is not added to the skin conditioner.
- the skin conditioner is composed of licorice extract and artemisia annua extract in a weight ratio of 6:13.
- the preparation method of the silver ion antibacterial hand sanitizer is similar to Example 2.
- Example 2 The difference from Example 2 is that sodium citrate is not added to the skin conditioner.
- the silver ion antibacterial hand sanitizer is composed of the following components and parts by weight:
- the skin conditioner is composed of licorice extract, artemisia annua extract and sodium citrate in a weight ratio of 1:1:1.
- the preparation method of the silver ion antibacterial hand sanitizer is similar to Example 2.
- Example 2 The difference from Example 2 is that the skin conditioner is composed of licorice extract, artemisia annua extract and sodium citrate in a weight ratio of 1:1:1.
- Test example one antibacterial performance test
- Test materials silver ion antibacterial hand soap prepared in Examples 1-3 and Comparative Examples 1-3.
- Test method antibacterial experiment: place 3 mL of silver ion antibacterial hand sanitizer prepared in Example 1-3 and Comparative Example 1-3 in an Erlenmeyer flask, and then add 70 mL of phosphate buffer (0.03mol ⁇ L -1 ) and 5 mL of bacterial liquid. After the liquid is infiltrated into the culture medium, the colony is counted after incubating at 37°C for 2 minutes.
- X (A-B)/A ⁇ 100%, where X is the inhibition rate, A is the average number of colonies before the sample shakes, and B is the average number of colonies after the test sample shakes.
- Test materials Silver ion antibacterial hand soap prepared in Example 2, Comparative Examples 1-3.
- the silver ion antibacterial hand sanitizer prepared in Example 2 has no change in odor and color under the detection conditions of heat resistance (40 ⁇ 1°C) and cold resistance (-5 ⁇ 0°C), and no precipitation or suspension.
- the appearance of the substance and the uniform texture indicate that the hand sanitizer of the present invention is in a stable state.
- Comparative Examples 1-3 when the composition of the skin conditioner was changed, the silver ion antibacterial hand sanitizer showed turbidity, flocculent, and solution stratification to varying degrees under the same conditions.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
涉及一种银离子抑菌洗手液及其制备方法和应用。所提供的银离子抑菌洗手液包括以下重量份数的原料组成：银0.01～0.03份、硫酸银0.02～0.08份、保湿剂1～5份、皮肤调理剂10～18份、防腐剂0.3～0.8份、十二烷基苯磺酸钠0.1～0.5份、乙基己基甘油0.8～1.8份、丙二醇1～5份、壬基酚聚醚-14 3～6份、PEG-50蓖麻油1～6份、香精0.01～0.05份和去离子水80～120份。所述银离子抑菌洗手液可以用于手部消毒，高效抑菌、除菌和止痒，性能温和，不刺激，且能够保持手部滋润。
Description
本发明属于卫生清洁用品技术领域，具体涉及一种银离子抑菌洗手液及其制备方法和应用。
银系抗菌剂有着很长的应用历史，对人类的健康发挥了很大的作用。并且就安全性和抗菌效果而言，无机银系抗菌剂及银系复合抗菌剂更具长效、高效、广谱和安全等优势。早在古代人们就发现了银具有天然的抗菌性和安全性。那时，古埃及人知道用薄银片覆盖伤口来防止细菌感染，加速伤口愈合蒙古族人知道用银器盛装羊奶可以保鲜我国明代医学家李时珍在《本草纲目》中记述银屑有安五脏、定心神、止惊悸、除邪气等作用久服能轻身延年，生银味辛寒、无毒中医用银诊治有关疾病,西医用银治疡的记载也有100余年。研究发现，银对各种致病细菌如大肠杆菌、金黄色葡萄球菌等都有很强的杀灭效果，而且所需浓度极低，一般用量为10-6(质量分数)即可灭菌。在安全性方面，银为人体内的组织成分之一，用浓度很低的银离子处理后的细胞没有明显的细胞聚集、细胞变形、细胞溶解和pH值等的变化，可见少量的银离子对人体没有明显的伤害作用。因此将银系抗菌剂用于纺织品的抗菌功能改进方面，具有足够的安全性。
由于无机抗菌剂具有抗菌广谱、持久、安全、无耐药性等特点，所以人们对它的研究与应用已越来越被许多国家所重视。人们对银的抗菌机理总结如下：1、银与致病菌代谢酶中的巯基结合，使酶失活，致使致病菌不能代谢而死亡；2、银和细菌细胞壁上暴露的肽聚糖反应，形成可逆性复合物，使其不能把氧转运进细胞，阻止病菌活动，导致其死亡；3、银离子和致病菌中的DNA碱基结合，银离子彼此形成交叉链接，导致DNA结构变性，抑制其复制，使致病菌失活。
人类疾病的发生根源于手部接触细菌，所以手部消毒清洁至关重要，是预防病菌传播的有效措施。勤洗手是控制疾病的传播和防止感染最有效、最简单可行的方法，对消化道传播的疾病和经呼吸道传播的疾病都有良好的预防作用。且大量流行病学调查证实，手是医院感染的重要途径。医护人员在护理、诊疗活动后手上细菌污染严重，医院感染可通过医护人员手直接或间接传播，并且这一途径比空气传播更具危险性，导致细菌传播而造成感染者占医院感染发生率的30％。
中国专利申请CN 101766552 A公开了一种免洗抗菌洗手液及其制备方法，包括氯己定盐1g～10g、硝酸银5ug～1000ug、醇类物质30～90ml、护肤剂2g～50g、增粘剂0.5g～3g、表面活性剂0.5g～3g、p+H调节剂0.5g～5g、去离子水15ml～50ml。但是该产品消毒成分单一，不具有协同抗菌作用和较强的光谱抑菌、杀菌作用，无法长效抑菌，且对皮肤可能会产生一定的刺激性。
因此，为解决上述技术问题，确有必要提供一种银离子抑菌洗手液，以克服传统洗手液的所述缺陷，能够高效抑菌、除菌和止痒，性能温和，不刺激，且能够保持手部滋润。
发明内容
为了解决现有技术中存在的问题，本发明的目的在于提供一种银离子抑菌洗手液及其制备方法。本发明提供的银离子抑菌洗手液杀菌效果好，具有滞留性，并可杀病毒，可持续杀灭皮肤、汗腺、毛囊中逸出的微生物，同时性能温和，稳定性高，不刺激，且能够保持手部滋润。
本发明的技术方案是：
一种银离子抑菌洗手液，包括如下组分及其重量份数：
银0.01～0.03份、硫酸银0.02～0.08份、保湿剂1～5份、皮肤调理剂10～18份、防腐剂0.3～0.8份、十二烷基苯磺酸钠0.1～0.5份、乙基己基甘油0.8～1.8份、丙二醇1～5份、壬基酚聚醚-14 3～6份、PEG-50蓖麻油1～6份、香精0.01～0.05份和去离子水80～120份。
进一步地，所述的银离子抑菌洗手液，由如下组分及其重量份数组成：银0.02份、硫酸银0.05份、保湿剂3份、皮肤调理剂12份、防腐剂0.5份、十二烷基苯磺酸钠0.3份、乙基己基甘油1.2份、丙二醇3份、壬基酚聚醚-14 4份、PEG-50蓖麻油4份、香精0.02份和去离子水100份。
进一步地，所述保湿剂为甲基丙二醇。
进一步地，所述皮肤调理剂为甘草提取物、青蒿提取物和柠檬酸钠按重量比4～9:8～15:1～3组成。
更进一步地，所述皮肤调理剂为甘草提取物、青蒿提取物和柠檬酸钠按重量比6:13:2组成。
进一步地，所述防腐剂为苯氧乙醇。
另外，本发明还提供了一种所述的银离子抑菌洗手液的制备方法，所述制备步骤如下：
S1、将去离子水加热至70～80℃后，边搅拌边加入保湿剂、十二烷基苯磺酸钠、乙基己基甘油、丙二醇、壬基酚聚醚-14、PEG-50蓖麻油，在转速为800-1000r/min的速度下恒温搅拌20-30min，搅拌至完全溶解，得混合液I；
S2、将步骤S1所得的混合液I降温至20-30℃，再加入银、硫酸银、皮肤调理剂、防腐剂、香精，在压力为8-15MPa，转速为2000-2500r/min下均质20-60分钟，即得。
本发明提供的银离子抑菌洗手液中加入的皮肤调理剂的主要成分为植物提取物，有效增加了洗手液的抑菌性能，能够降低银离子的加入浓度，减少成本，并且银离子的加入既增加了抑菌广谱性，又增加了抑菌的持久性，与添加的植物提取物配合使用配合使用，杀菌效果好，抑菌时间长。
其中，添加的青蒿提取物含有黄酮类、香豆素、萜类、苯丙酸类和挥发油及其他类青蒿素等；具有抗疟、抗菌、抗病毒、抗炎、解热和镇痛、抗血吸虫及其他寄生虫、免疫、抑制肿瘤、影响心血管系统等药理作用；在临床上常用于疟疾、阴虚发热、骨蒸劳热、暑邪发热、慢性支气管炎、盘型红斑狼疮、口腔粘膜扁平苔癣、皮肤真菌病、神经性皮炎、皮肤瘙痒症、婴幼儿秋季腹泻、鼻衄等症状的治疗。并且青蒿水煎剂对表皮葡萄球菌、卡他球菌、炭疽杆菌、白喉杆菌，有较强的抑制作用。对金黄色葡萄球菌、绿脓、痢疾、结核等杆菌也有一定的抑制作用。青蒿挥发油在0.25％浓度时，对所有皮肤癣菌有抑制作用，1％浓度时，对所有皮肤癣菌有杀菌作用。
添加的甘草提取物，是从甘草中提取的有药用价值的成份。甘草提取物一般包含：甘草甜素、甘草酸，甘草甙、甘草类黄酮、后幕比檀素、刺芒柄花素、槲皮素等。有补脾益气，清热解毒，祛痰止咳，缓急止痛，调和诸药的功效。用于治疗脾胃虚弱，倦怠乏力，心悸气短，咳嗽痰多，脘腹、四肢挛急疼痛等病症。
同时，向皮肤调理剂中添加一定量的柠檬酸钠，能够增加青蒿提取物和甘草提取物的稳定性，有效增强了洗手液抑菌能力的同时，还能使得到的洗手液稳定性好，冷冻加热不会出现分层现象，性质可靠。
与现有技术相比，本发明提供的银离子抑菌洗手液具有以下优势：
(1)本发明提供的银离子抑菌洗手液具有杀菌、去污、抗菌、消毒的作用，还具有高效润肤成分，对皮肤滋润和保温，是一种温和低刺激的洗手液。
(2)本发明提供的银离子抑菌洗手液稳定性好，冷冻加热不会出现分层现象，性质可靠，并达到化工洗手液灭菌效果。并且使用方安全，无毒、无刺激、无不良气味。
(3)本发明提供的银离子抑菌洗手液通过银离子杀菌剂与植物提取物相结合的杀菌模式，杀菌效果好，具有滞留性，并可杀病毒，可持续杀灭皮肤、汗腺、毛囊中逸出的微生物，具有良好的后效应，杀菌同时可以消炎。
以下通过具体实施方式的描述对本发明作进一步说明，但这并非是对本发明的限制，本领域技术人员根据本发明的基本思想，可以做出各种修改或改进，但是只要不脱离本发明的基本思想，均在本发明的保护范围之内。
甘草提取物购自南京邦诺生物科技有限公司，青蒿提取物购自上海联迈生物工程有限公司。
本发明所用其余试剂均为常用试剂，均可在常规试剂生产销售公司购买。
实施例1 一种银离子抑菌洗手液
所述的银离子抑菌洗手液，由如下组分及其重量份数组成：
银0.01份、硫酸银0.02份、甲基丙二醇1份、皮肤调理剂10份、苯氧乙醇0.3份、十二烷基苯磺酸钠0.1份、乙基己基甘油0.8份、丙二醇1份、壬基酚聚醚-14 3份、PEG-50蓖麻油1份、香精0.01份和去离子水80份。
所述皮肤调理剂为甘草提取物、青蒿提取物和柠檬酸钠按重量比4:15:3组成。
所述的银离子抑菌洗手液的制备方法，所述制备步骤如下：
S1、将去离子水加热至70℃后，边搅拌边加入甲基丙二醇、十二烷基苯磺酸钠、乙基己基甘油、丙二醇、壬基酚聚醚-14、PEG-50蓖麻油，在转速为800r/min的速度下恒温搅拌20min，搅拌至完全溶解，得混合液I；
S2、将步骤S1所得的混合液I降温至20℃，再加入银、硫酸银、皮肤调理剂、苯氧乙醇、香精，在压力为8MPa，转速为2000r/min下均质20分钟，即得。
实施例2 一种银离子抑菌洗手液
所述的银离子抑菌洗手液，由如下组分及其重量份数组成：
银0.02份、硫酸银0.05份、甲基丙二醇3份、皮肤调理剂12份、苯氧乙醇0.5份、十二烷基苯磺酸钠0.3份、乙基己基甘油1.2份、丙二醇3份、壬基酚聚醚-14 4份、PEG-50蓖麻油4份、香精0.02份和去离子水100份。
所述皮肤调理剂为甘草提取物、青蒿提取物和柠檬酸钠按重量比6:13:2组成。
所述的银离子抑菌洗手液的制备方法，所述制备步骤如下：
S1、将去离子水加热至75℃后，边搅拌边加入甲基丙二醇、十二烷基苯磺酸钠、乙基己基甘油、丙二醇、壬基酚聚醚-14、PEG-50蓖麻油，在转速为900r/min的速度下恒温搅拌25min，搅拌至完全溶解，得混合液I；
S2、将步骤S1所得的混合液I降温至25℃，再加入银、硫酸银、皮肤调理剂、苯氧乙醇、香精，在压力为12MPa，转速为2300r/min下均质40分钟，即得。
实施例3 一种银离子抑菌洗手液
所述的银离子抑菌洗手液，由如下组分及其重量份数组成：
银0.03份、硫酸银0.08份、甲基丙二醇5份、皮肤调理剂18份、苯氧乙醇0.8份、十二烷基苯磺酸钠0.5份、乙基己基甘油1.8份、丙二醇5份、壬基酚聚醚-14 6份、PEG-50蓖麻油6份、香精0.05份和去离子水120份。
所述皮肤调理剂为甘草提取物、青蒿提取物和柠檬酸钠按重量比9:8:1组成。
所述的银离子抑菌洗手液的制备方法，所述制备步骤如下：
S1、将去离子水加热至80℃后，边搅拌边加入甲基丙二醇、十二烷基苯磺酸钠、乙基己基甘油、丙二醇、壬基酚聚醚-14、PEG-50蓖麻油，在转速为1000r/min的速度下恒温搅拌30min，搅拌至完全溶解，得混合液I；
S2、将步骤S1所得的混合液I降温至30℃，再加入银、硫酸银、皮肤调理剂、苯氧乙醇、香精，在压力为15MPa，转速为2500r/min下均质60分钟，即得。
对比例1 一种银离子抑菌洗手液
所述的银离子抑菌洗手液，由如下组分及其重量份数组成：
银0.02份、硫酸银0.05份、甲基丙二醇3份、皮肤调理剂12份、苯氧乙醇0.5份、十二烷基苯磺酸钠0.3份、乙基己基甘油1.2份、丙二醇3份、壬基酚聚醚-14 4份、PEG-50蓖麻油4份、香精0.02份和去离子水100份。
所述皮肤调理剂为甘草提取物和柠檬酸钠按重量比6:2组成。
所述的银离子抑菌洗手液的制备方法与实施例2类似。
与实施例2的区别在于，所述的皮肤调理剂中未添加青蒿提取物。
对比例2 一种银离子抑菌洗手液
所述的银离子抑菌洗手液，由如下组分及其重量份数组成：
银0.02份、硫酸银0.05份、甲基丙二醇3份、皮肤调理剂12份、苯氧乙醇0.5份、十二烷基苯磺酸钠0.3份、乙基己基甘油1.2份、丙二醇3份、壬基酚聚醚-14 4份、PEG-50蓖麻油4份、香精0.02份和去离子水100份。
所述皮肤调理剂为甘草提取物、青蒿提取物按重量比6:13组成。
所述的银离子抑菌洗手液的制备方法与实施例2类似。
与实施例2的区别在于，所述的皮肤调理剂中未添加柠檬酸钠。
对比例3 一种银离子抑菌洗手液
所述的银离子抑菌洗手液，由如下组分及其重量份数组成：
银0.02份、硫酸银0.05份、甲基丙二醇3份、皮肤调理剂12份、苯氧乙醇0.5份、十二烷基苯磺酸钠0.3份、乙基己基甘油1.2份、丙二醇3份、壬基酚聚醚-14 4份、PEG-50蓖麻油4份、香精0.02份和去离子水100份。
所述皮肤调理剂为甘草提取物、青蒿提取物和柠檬酸钠按重量比1:1:1组成。
所述的银离子抑菌洗手液的制备方法与实施例2类似。
与实施例2的区别在于，所述皮肤调理剂为甘草提取物、青蒿提取物和柠檬酸钠按重量比1:1:1组成。
试验例一、抑菌性能测试
1.试验材料：实施例1-3，对比例1-3制备的银离子抑菌洗手液。
2.试验对象：大肠杆菌，白色念珠菌，金黄色葡萄球菌，铜绿假单胞菌。
3.试验方法：抗菌实验：将实施例1-3和对比例1-3制备的3mL银离子抑菌洗手液分别置于锥形瓶内，然后分别加入70mL磷酸盐缓冲液(0.03mol·L
-1)和5mL菌液，待液体渗入培养基中后，37℃培养2min后，进行菌落计数。
抑菌率计算公式：X＝(A-B)/A×100％，其中X为抑菌率，A为试样振荡前平均菌落数，B为试样品振荡后平均菌落数。
4.试验结果
试验结果如表1所示。
表1 银离子抑菌洗手液抑菌试验结果
由表1可知：在2min内，实施例1-3制备的银离子抑菌洗手液对于大肠杆菌、白色念珠菌、金黄色葡萄球菌、铜绿假单胞菌的抑菌率均在99.9％以上，说明本发明制备的银离子抑菌洗手液具有良好的杀菌抗菌作用。而对比例1-3与实施例组的试验结果表明，当改变了本发明提供的皮肤调理剂的组分时，制得的洗手液在2min内的抗菌效果明显下降，说明本发明提供的皮肤调理剂各组分缺一不可，协同作用明显。
试验例二、稳定性测定
1.试验材料：实施例2，对比例1-3制备的银离子抑菌洗手液。
2、试验内容：将实施例2、对比例1-3制备的银离子抑菌洗手液5g放置到恒温箱中，均处理24h后，取出待温度恢复至室温，观察结果。
3、试验结果
实验结果如表1所示。
表2 稳定性测试结果
由表2可知，实施例2制备的银离子抑菌洗手液在耐热(40±1℃)以及耐寒(-5～0℃)的检测条件下的气味、颜色均无变化，无沉淀及悬浮物出现，质地均匀，说明本发明的洗手液状态稳定。而对比例1-3中，当改变了皮肤调理剂的组成时，在相同条件下银离子抑菌洗手液均不同程度出现了浑浊和絮状物，溶液分层等现象。
上述实施例仅例示性说明本发明的原理及其功效，而非用于限制本发明。任何熟悉此技术的人士皆可在不违背本发明的精神及范畴下，对上述实施例进行修饰或改变。因此，举凡所属技术领域中具有通常知识者在未脱离本发明所揭示的精神与技术思想下所完成的一切等效修饰或改变，仍应由本发明的权利要求所涵盖。
Claims (7)
- 一种银离子抑菌洗手液，其特征在于，包括如下组分及其重量份数：银0.01～0.03份、硫酸银0.02～0.08份、保湿剂1～5份、皮肤调理剂10～18份、防腐剂0.3～0.8份、十二烷基苯磺酸钠0.1～0.5份、乙基己基甘油0.8～1.8份、丙二醇1～5份、壬基酚聚醚-14 3～6份、PEG-50蓖麻油1～6份、香精0.01～0.05份和去离子水80～120份。
- 如权利要求1所述的银离子抑菌洗手液，其特征在于，由如下组分及其重量份数组成：银0.02份、硫酸银0.05份、保湿剂3份、皮肤调理剂12份、防腐剂0.5份、十二烷基苯磺酸钠0.3份、乙基己基甘油1.2份、丙二醇3份、壬基酚聚醚-14 4份、PEG-50蓖麻油4份、香精0.02份和去离子水100份。
- 如权利要求1或2所述的银离子抑菌洗手液，其特征在于，所述保湿剂为甲基丙二醇。
- 如权利要求1或2所述的银离子抑菌洗手液，其特征在于，所述皮肤调理剂为甘草提取物、青蒿提取物和柠檬酸钠按重量比4～9:8～15:1～3组成。
- 如权利要求4所述的银离子抑菌洗手液，其特征在于，所述皮肤调理剂为甘草提取物、青蒿提取物和柠檬酸钠按重量比6:13:2组成。
- 如权利要求1或2所述的银离子抑菌洗手液，其特征在于，所述防腐剂为苯氧乙醇。
- 一种如权利要求1-6任一项所述的银离子抑菌洗手液的制备方法，其特征在于，所述制备步骤如下：S1、将去离子水加热至70～80℃后，边搅拌边加入保湿剂、十二烷基苯磺酸钠、乙基己基甘油、丙二醇、壬基酚聚醚-14、PEG-50蓖麻油，在转速为800-1000r/min的速度下恒温搅拌20-30min，搅拌至完全溶解，得混合液I；S2、将步骤S1所得的混合液I降温至20-30℃，再加入银、硫酸银、皮肤调理剂、防腐剂、香精，在压力为8-15MPa，转速为2000-2500r/min下均质20-60分钟，即得。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010582337.3A CN111603422B (zh) | 2020-06-23 | 2020-06-23 | 一种银离子抑菌洗手液及其制备方法和应用 |
| CN202010582337.3 | 2020-06-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021258654A1 true WO2021258654A1 (zh) | 2021-12-30 |
Family
ID=72201000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2020/134259 WO2021258654A1 (zh) | 2020-06-23 | 2020-12-07 | 一种银离子抑菌洗手液及其制备方法和应用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11173101B1 (zh) |
| KR (1) | KR102251911B1 (zh) |
| CN (1) | CN111603422B (zh) |
| LU (1) | LU102388B1 (zh) |
| WO (1) | WO2021258654A1 (zh) |
| ZA (1) | ZA202100288B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111603422B (zh) * | 2020-06-23 | 2021-03-16 | 乐比(广州)健康产业有限公司 | 一种银离子抑菌洗手液及其制备方法和应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005077329A1 (en) * | 2004-02-11 | 2005-08-25 | Amorepacific Corporation | Silver/polymer colloidal nanocomposites and a process for preparation of the same, and cosmetic compositions containing the same |
| CN102600053A (zh) * | 2012-04-01 | 2012-07-25 | 西北师范大学 | 中草药-无机抗菌剂复合杀菌洗手液及其制备 |
| CN105308167A (zh) * | 2013-04-16 | 2016-02-03 | 荷兰联合利华有限公司 | 具有增强的抗菌活性的液体皂 |
| CN106414692A (zh) * | 2014-01-29 | 2017-02-15 | 荷兰联合利华有限公司 | 含有微动金属与增效剂的清洁组合物 |
| CN107468595A (zh) * | 2017-09-29 | 2017-12-15 | 洛娃日化(江苏)股份有限公司 | 一种植物抑菌洗手液及制备方法 |
| CN111603422A (zh) * | 2020-06-23 | 2020-09-01 | 广州市华晟健康产业有限公司 | 一种银离子抑菌洗手液及其制备方法和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6257668B2 (ja) * | 2015-08-31 | 2018-01-10 | アース製薬株式会社 | 銀担持体からの銀溶出向上剤 |
| JP7341834B2 (ja) * | 2018-10-05 | 2023-09-11 | 大阪ガスケミカル株式会社 | 化粧料組成物及びその製造方法、並びに化粧料 |
-
2020
- 2020-06-23 CN CN202010582337.3A patent/CN111603422B/zh active Active
- 2020-12-07 LU LU102388A patent/LU102388B1/en active IP Right Grant
- 2020-12-07 WO PCT/CN2020/134259 patent/WO2021258654A1/zh active Application Filing
-
2021
- 2021-01-15 ZA ZA2021/00288A patent/ZA202100288B/en unknown
- 2021-03-04 KR KR1020210028545A patent/KR102251911B1/ko active IP Right Grant
- 2021-05-21 US US17/326,485 patent/US11173101B1/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005077329A1 (en) * | 2004-02-11 | 2005-08-25 | Amorepacific Corporation | Silver/polymer colloidal nanocomposites and a process for preparation of the same, and cosmetic compositions containing the same |
| CN102600053A (zh) * | 2012-04-01 | 2012-07-25 | 西北师范大学 | 中草药-无机抗菌剂复合杀菌洗手液及其制备 |
| CN105308167A (zh) * | 2013-04-16 | 2016-02-03 | 荷兰联合利华有限公司 | 具有增强的抗菌活性的液体皂 |
| CN106414692A (zh) * | 2014-01-29 | 2017-02-15 | 荷兰联合利华有限公司 | 含有微动金属与增效剂的清洁组合物 |
| CN107468595A (zh) * | 2017-09-29 | 2017-12-15 | 洛娃日化(江苏)股份有限公司 | 一种植物抑菌洗手液及制备方法 |
| CN111603422A (zh) * | 2020-06-23 | 2020-09-01 | 广州市华晟健康产业有限公司 | 一种银离子抑菌洗手液及其制备方法和应用 |
Non-Patent Citations (1)
| Title |
|---|
| GUANGZHOU HUASHENG HEALTH INDUSTRY CO., LTD.: "Zhongzhi silver ion hand sanitizer (Record number Guangdong G makeup network prepared word 2020021827)", CHINA DOMESTIC NON-SPECIAL USE COSMETICS RECORD FILING, no. 2020021827, 2020021827, 18 February 2020 (2020-02-18), XP009533279 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102251911B1 (ko) | 2021-05-12 |
| CN111603422A (zh) | 2020-09-01 |
| US11173101B1 (en) | 2021-11-16 |
| CN111603422B (zh) | 2021-03-16 |
| ZA202100288B (en) | 2021-10-27 |
| LU102388B1 (en) | 2021-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2155222T3 (en) | Extract of Trigonella foenum-graecum | |
| CN105504966A (zh) | 一种新型平版胶印油墨 | |
| WO2021179567A1 (zh) | 一种舒缓咽喉疼痛的艾叶复合精油及其制备方法 | |
| CN108888758A (zh) | 胶原蛋白妇科洗液及其制备方法 | |
| CN111150778A (zh) | 一种具有对口腔粘膜、皮肤和一般物品高效、高安全性的杀菌消毒液及其制备方法 | |
| WO2023061416A1 (zh) | 一种组合物及其抗菌应用 | |
| CN102861206A (zh) | 皮肤粘膜杀菌消毒气雾剂及其制备方法 | |
| CN114028546A (zh) | 复合多肽杀菌制剂及其制备方法和用途 | |
| WO2021258654A1 (zh) | 一种银离子抑菌洗手液及其制备方法和应用 | |
| JP2023547727A (ja) | 経鼻投与用消毒剤組成物 | |
| CN114306526B (zh) | 一种复方苦丁茶中药提取物及其在制备沐浴露或洗手液中的应用 | |
| CN109602868A (zh) | 植物精华液及其制备方法和卫生巾应用 | |
| CN108938703A (zh) | 快速抗菌的妇科凝胶 | |
| CN111481567B (zh) | 一种复方臭氧油及其制备方法和应用 | |
| CN109432204B (zh) | 一种银离子喷雾及其制备方法 | |
| CN107308104A (zh) | 一种妇科凝胶的制备方法 | |
| CN106344453A (zh) | 一种新型祛痘膏及其制备方法 | |
| CN111035684A (zh) | 一种臭氧油复方鼻炎凝胶及其制备方法 | |
| CN101757119B (zh) | 一种治疗阴道炎的药物组合物、凝胶剂及其制备方法 | |
| CN111012703A (zh) | 一种纯天然pH平衡护理液及其制备方法 | |
| CN107469038A (zh) | 一种治疗脚气的乳膏及其制备方法 | |
| CN108635283A (zh) | 抑菌组合物、抑菌牙膏及其制备方法 | |
| CN107802799A (zh) | 一种医用消毒液 | |
| CN114533797B (zh) | 一种清咽组合物、清咽抑菌液及制备方法和应用 | |
| CN107149611A (zh) | 一种蒙药鼻炎喷雾剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20942349 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 22/05/2023) |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20942349 Country of ref document: EP Kind code of ref document: A1 |